Trial Outcomes & Findings for A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (NCT NCT04680052)

NCT ID: NCT04680052

Last Updated: 2025-12-22

Results Overview

PD, positron emission tomography (PET): score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, computed tomography (CT): abnormal individual node/lesion with longest diameter (LDi ) \>1.5 centimeters (cm) and increase by ≥50% from the product of the perpendicular diameters (PPD) nadir and increase in LDi or shortest diameter (SDi) from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node \>1.5 cm in any axis. New extranodal site \>1.0 cm in any axis; if \<1.0 cm, presence is unequivocal and attributable to lymphoma.

• Recruitment status: ACTIVE_NOT_RECRUITING
• Study phase: PHASE3
• Target enrollment: 654 participants
• Primary outcome timeframe: up to approximately 34 months
• Results posted on: 2025-12-22

Participant Flow

Participant milestones

Measure	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Placebo + Rituximab + Lenalidomide Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Study STARTED	53	273	275	53
Overall Study COMPLETED	0	0	0	0
Overall Study NOT COMPLETED	53	273	275	53

Reasons for withdrawal

Measure	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Placebo + Rituximab + Lenalidomide Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Study Ongoing	46	244	229	39
Overall Study Death	1	15	22	7
Overall Study Lost to Follow-up	1	3	2	0
Overall Study Withdrawal by Subject	5	11	19	7
Overall Study Missing	0	0	1	0
Overall Study Hypersensitivity to Rituximab; Did Not Receive Treatment	0	0	1	0
Overall Study Physician Decision	0	0	1	0

Baseline Characteristics

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Baseline characteristics by cohort

Measure	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide n=275 Participants Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Placebo + Rituximab + Lenalidomide n=53 Participants Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide n=53 Participants Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	Total n=654 Participants Total of all reporting groups
Age, Continuous	64.6 years STANDARD_DEVIATION 10.89 • n=18 Participants	63.7 years STANDARD_DEVIATION 11.69 • n=102 Participants	68.3 years STANDARD_DEVIATION 10.69 • n=30 Participants	67.9 years STANDARD_DEVIATION 11.40 • n=37 Participants	64.8 years STANDARD_DEVIATION 11.33 • n=127 Participants
Sex: Female, Male Female	123 Participants n=18 Participants	126 Participants n=102 Participants	27 Participants n=30 Participants	26 Participants n=37 Participants	302 Participants n=127 Participants
Sex: Female, Male Male	150 Participants n=18 Participants	149 Participants n=102 Participants	26 Participants n=30 Participants	27 Participants n=37 Participants	352 Participants n=127 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	31 Participants n=18 Participants	24 Participants n=102 Participants	4 Participants n=30 Participants	8 Participants n=37 Participants	67 Participants n=127 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	228 Participants n=18 Participants	226 Participants n=102 Participants	45 Participants n=30 Participants	41 Participants n=37 Participants	540 Participants n=127 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	14 Participants n=18 Participants	25 Participants n=102 Participants	4 Participants n=30 Participants	4 Participants n=37 Participants	47 Participants n=127 Participants
Race/Ethnicity, Customized White	219 Participants n=18 Participants	219 Participants n=102 Participants	43 Participants n=30 Participants	41 Participants n=37 Participants	522 Participants n=127 Participants
Race/Ethnicity, Customized Black or African-American	1 Participants n=18 Participants	0 Participants n=102 Participants	0 Participants n=30 Participants	1 Participants n=37 Participants	2 Participants n=127 Participants
Race/Ethnicity, Customized Asian	40 Participants n=18 Participants	42 Participants n=102 Participants	7 Participants n=30 Participants	6 Participants n=37 Participants	95 Participants n=127 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=18 Participants	0 Participants n=102 Participants	0 Participants n=30 Participants	1 Participants n=37 Participants	1 Participants n=127 Participants
Race/Ethnicity, Customized Not Reported	11 Participants n=18 Participants	10 Participants n=102 Participants	3 Participants n=30 Participants	4 Participants n=37 Participants	28 Participants n=127 Participants
Race/Ethnicity, Customized Captured as "Other" in Database	2 Participants n=18 Participants	4 Participants n=102 Participants	0 Participants n=30 Participants	0 Participants n=37 Participants	6 Participants n=127 Participants

PRIMARY outcome

Timeframe: up to approximately 34 months

Population: Follicular Lymphoma (FL) Full Analysis Set: all randomized participants with FL. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Censored participants were included in the analysis.

PD, positron emission tomography (PET): score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, computed tomography (CT): abnormal individual node/lesion with longest diameter (LDi ) >1.5 centimeters (cm) and increase by ≥50% from the product of the perpendicular diameters (PPD) nadir and increase in LDi or shortest diameter (SDi) from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First	13.93 months Interval 11.53 to 16.39	22.37 months Interval 19.22 to The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.	—	—

PRIMARY outcome

Timeframe: up to 2 years

Population: FL Full Analysis Set. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 6 months	78.2 percent probability Interval 72.7 to 82.7	92.4 percent probability Interval 88.3 to 95.1	—	—
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 12 months	54.0 percent probability Interval 47.1 to 60.5	79.0 percent probability Interval 72.8 to 84.0	—	—
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 18 months	38.5 percent probability Interval 30.8 to 46.1	61.9 percent probability Interval 53.4 to 69.3	—	—
FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 2 years	31.8 percent probability Interval 23.6 to 40.2	41.7 percent probability Interval 28.4 to 54.6	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Censored participants were included in the analysis.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First	16.39 months Interval 13.86 to 18.66	23.95 months Interval 22.34 to The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 6 months	80.0 percent probability Interval 75.0 to 84.0	92.7 percent probability Interval 89.0 to 95.1	—	—
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 12 months	58.7 percent probability Interval 52.4 to 64.4	79.7 percent probability Interval 74.1 to 84.2	—	—
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 18 months	44.7 percent probability Interval 37.6 to 51.5	64.1 percent probability Interval 56.7 to 70.6	—	—
Overall Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 2 years	33.1 percent probability Interval 24.1 to 42.3	48.0 percent probability Interval 36.1 to 59.0	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL FDG-avid Set: all randomized participants with FL and with a PET scan at Baseline with a resulting Deauville score of 4 or 5. Participants who did not have a post-baseline PET scan were considered to be "not assessed," but were included in the analysis. The 95% confidence intervals were calculated using the Clopper-Pearson method.

CR was defined as a complete metabolic response at any time after the start of treatment. Per PET, CR criteria: (1) score of 1, 2, or 3 with or without a residual mass on a 5-point scale for lymph nodes and extralymphatic sites; (2) No evidence of FDG-avid disease in bone marrow; and (3) no new lesions. PET 5-point scale: 1 = no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake > mediastinum but ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly higher than liver and/or new lesions; X = new areas of uptake unlikely to be related to lymphoma.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=254 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=251 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FDG-avid FL Population: Positron Emission Tomography-Complete Response (PET-CR) Rate by Investigator Assessment, Using the Lugano 2014 Criteria	39.8 percentage of participants Interval 33.7 to 46.07	49.4 percentage of participants Interval 43.06 to 55.76	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Censored participants were included in the analysis.

Overall survival was defined as the time from randomization until death from any cause.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Overall Survival	NA months The median and the upper and lower limits of the confidence interval were not estimable because too few participants died.	NA months Interval 27.93 to The median and the upper limit of the confidence interval were not estimable because too few participants died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: FL Full Analysis Set. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

Overall survival was defined as the time from randomization until death from any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Kaplan-Meier Estimates of Overall Survival 2 years	85.5 percent probability Interval 76.2 to 91.4	92.5 percent probability Interval 87.0 to 95.8	—	—
FL Population: Kaplan-Meier Estimates of Overall Survival 6 months	96.2 percent probability Interval 93.1 to 98.0	99.3 percent probability Interval 97.1 to 99.8	—	—
FL Population: Kaplan-Meier Estimates of Overall Survival 12 months	93.7 percent probability Interval 90.0 to 96.1	96.4 percent probability Interval 92.8 to 98.2	—	—
FL Population: Kaplan-Meier Estimates of Overall Survival 18 months	90.1 percent probability Interval 84.8 to 93.6	93.8 percent probability Interval 89.1 to 96.5	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall FDG-avid Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Participants who did not have a post-baseline PET scan were considered to be "not assessed," but were included in the analysis. The 95% confidence intervals were calculated using the Clopper-Pearson method.

CR was defined as a complete metabolic response at any time after the start of treatment. Per PET, CR criteria: (1) score of 1, 2, or 3 with or without a residual mass on a 5-point scale for lymph nodes and extralymphatic sites; (2) No evidence of FDG-avid disease in bone marrow; and (3) no new lesions. PET 5-point scale: 1 = no uptake above background; 2 = uptake ≤ mediastinum; 3 = uptake > mediastinum but ≤ liver; 4 = uptake moderately > liver; 5 = uptake markedly higher than liver and/or new lesions; X = new areas of uptake unlikely to be related to lymphoma. The Overall FDG-avid Set included all randomized participants with a PET scan at Baseline with a resulting Deauville score of 4 or 5.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=293 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=290 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FDG-avid Overall Population: PET-CR Rate by Investigator Assessment, Using the Lugano 2014 Criteria	41.3 percentage of participants Interval 35.6 to 47.17	50.7 percentage of participants Interval 44.78 to 56.58	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL MRD Blood-Evaluable Set: all participants in the Full Analysis Set with FL who received at least 1 dose of study treatment with identifiable clonality in blood samples at Cycle 1 Day 1. The 95% confidence intervals were calculated using the Clopper-Pearson method. Participants who did not have a post-baseline assessment were considered to be "not assessed," but were included in the analysis.

The MRD-negativity rate was defined as the percentage of participants who achieved a negative MRD result in peripheral blood at the End of Treatment. The threshold used for the analysis was 10^-5 cells. MRD status was only analyzed with a threshold of ≤10^-5 cells for MRD negativity.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=66 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=57 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Minimal Residual Disease (MRD)-Negativity Rate (at Threshold of 10^-5) at End of Treatment	18.2 percentage of participants Interval 9.76 to 29.61	26.3 percentage of participants Interval 15.54 to 39.66	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall MRD Blood-Evaluable Set. As pre-specified in the Statistical Analysis Plan, the MZL population was a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 95% confidence intervals were calculated using the Clopper-Pearson method. Participants who did not have a post-baseline assessment were considered to be "not assessed," but were included in the analysis.

The MRD-negativity rate was defined as the percentage of participants who achieved a negative MRD result in peripheral blood at the End of Treatment. The threshold used for the analysis was 10^-5 cells. MRD status was only analyzed with a threshold of ≤10^-5 cells for MRD negativity. The Overall MRD Blood-Evaluable Set included all participants in the Full Analysis Set who received at least 1 dose of study treatment with identifiable clonality in blood samples at Cycle 1 Day 1.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=86 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=74 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: MRD-negativity Rate (at Threshold of 10-5) at End of Treatment	15.1 percentage of participants Interval 8.3 to 24.46	21.6 percentage of participants Interval 12.89 to 32.72	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. The 95% confidence intervals were calculated using the Clopper-Pearson method.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Overall Response Rate (Percentage of Participants Who Achieved a CR/PR Per the Lugano Classification at Any Time During the Study But Before the First PD and Before/at the Start of a New Antilymphoma Treatment) by Investigator Assessment	72.4 percentage of participants Interval 66.67 to 77.56	83.5 percentage of participants Interval 78.57 to 87.72	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 95% confidence intervals were calculated using the Clopper-Pearson method.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Overall Response Rate (Percentage of Participants Who Achieved a CR/PR Per Lugano Classification at Any Time During the Study But Before the First PD and Before/at the Start of a New Antilymphoma Treatment) by Investigator Assessment	72.0 percentage of participants Interval 66.75 to 76.75	82.8 percentage of participants Interval 78.28 to 86.76	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Only those participants who achieved an objective response (CR or PR) were analyzed.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=199 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=228 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Duration of Response (DOR; the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment	13.60 months Interval 12.42 to 18.56	21.19 months Interval 19.48 to The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: FL Full Analysis Set. Only those participants who achieved an objective response (CR or PR) were analyzed. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=199 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=228 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 6 months	77.8 percent probability Interval 70.9 to 83.2	91.5 percent probability Interval 86.6 to 94.6	—	—
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 12 months	59.1 percent probability Interval 50.3 to 66.9	76.3 percent probability Interval 68.4 to 82.4	—	—
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 18 months	42.9 percent probability Interval 33.1 to 52.4	63.7 percent probability Interval 53.4 to 72.2	—	—
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 2 years	33.3 percent probability Interval 20.5 to 46.6	39.5 percent probability Interval 21.4 to 57.1	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Only participants who achieved an objective response (CR or PR) were analyzed.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=236 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=270 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment	17.77 months Interval 13.37 to 19.88	22.24 months Interval 19.81 to The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: Overall Full Analysis Set. Per the SAP, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population (main analysis population). Participants who achieved CR or PR were analyzed. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=236 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=270 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 6 months	80.5 percent probability Interval 74.6 to 85.3	90.8 percent probability Interval 86.3 to 93.8	—	—
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 12 months	64.4 percent probability Interval 56.6 to 71.1	78.1 percent probability Interval 71.4 to 83.4	—	—
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 18 months	47.6 percent probability Interval 38.4 to 56.2	66.6 percent probability Interval 57.8 to 73.9	—	—
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by Investigator Assessment 2 years	35.1 percent probability Interval 23.0 to 47.4	43.4 percent probability Interval 27.2 to 58.6	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Censored participants were included in the analysis.

Overall survival was defined as the time from randomization until death from any cause.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Overall Survival	NA months The median and the upper and lower limits of the confidence interval were not estimable because too few participants died.	NA months The median and the upper and lower limits of the confidence interval were not estimable because too few participants died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

Overall survival was defined as the time from randomization until death from any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Kaplan-Meier Estimates of Overall Survival 2 years	88.3 percent probability Interval 81.1 to 92.8	90.1 percent probability Interval 84.4 to 93.7	—	—
Overall Population: Kaplan-Meier Estimates of Overall Survival 2 months	94.4 percent probability Interval 91.2 to 96.5	96.4 percent probability Interval 93.4 to 98.1	—	—
Overall Population: Kaplan-Meier Estimates of Overall Survival 18 months	91.7 percent probability Interval 87.4 to 94.5	92.2 percent probability Interval 87.7 to 95.1	—	—
Overall Population: Kaplan-Meier Estimates of Overall Survival 6 months	96.5 percent probability Interval 93.8 to 98.1	98.7 percent probability Interval 96.7 to 99.5	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Censored participants were included in the analysis.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First	16.00 months Interval 13.86 to 21.06	NA months Interval 19.29 to The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: FL Full Analysis Set. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 6 months	80.3 percent probability Interval 74.9 to 84.7	94.0 percent probability Interval 90.2 to 96.3	—	—
FL Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 12 months	59.8 percent probability Interval 52.9 to 66.1	83.1 percent probability Interval 77.1 to 87.7	—	—
FL Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 18 months	45.8 percent probability Interval 37.3 to 53.8	67.5 percent probability Interval 58.8 to 74.8	—	—
FL Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 2 years	35.0 percent probability Interval 24.7 to 45.6	53.9 percent probability Interval 41.9 to 64.4	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Censored participants were included in the analysis.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First	20.73 months Interval 15.38 to 23.1	NA months Interval 22.08 to The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PD, PET: score 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) for lymph node/extra lymphatic sites with increase in intensity of Baseline uptake and/or new FDG-avid foci consistent with lymphoma at interim/end-of-treatment assessment; new/recurrent FDG-avid foci in bone marrow; new FDG-avid foci consistent with lymphoma versus other etiology in new lesions. PD, CT: abnormal individual node/lesion with LDi >1.5 cm and increase by ≥50% from the PPD nadir and increase in LDi or SDi from nadir; new/clear progression of preexisting nontarget lesions; new/recurrent splenomegaly and bone marrow involvement; regrowth of previously resolved lesions. New node >1.5 cm in any axis. New extranodal site >1.0 cm in any axis; if <1.0 cm, presence is unequivocal and attributable to lymphoma. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 6 months	82.5 percent probability Interval 77.7 to 86.4	93.9 percent probability Interval 90.4 to 96.1	—	—
Overall Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 12 months	63.7 percent probability Interval 57.5 to 69.3	84.5 percent probability Interval 79.2 to 88.5	—	—
Overall Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 18 months	52.0 percent probability Interval 44.5 to 59.0	68.9 percent probability Interval 61.1 to 75.4	—	—
Overall Population: Kaplan-Meier Estimates of PFS by IRC Review, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First 2 years	38.8 percent probability Interval 28.3 to 49.1	56.0 percent probability Interval 45.1 to 65.6	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. The 95% confidence intervals were calculated using the Clopper-Pearson method.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Overall Response Rate (Percentage of Participants Who Achieved a CR/PR Per the Lugano Classification at Any Time During the Study But Before the First PD and Before/at the Start of a New Antilymphoma Treatment) by IRC Review	73.5 percentage of participants Interval 67.82 to 78.58	85.7 percentage of participants Interval 80.99 to 89.64	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 95% confidence intervals were calculated using the Clopper-Pearson method.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Overall Response Rate (Percentage of Participants Who Achieved a CR/PR Per Lugano Classification at Any Time During the Study But Before the First PD and Before/at the Start of a New Antilymphoma Treatment) by IRC Review	72.6 percentage of participants Interval 67.39 to 77.32	83.7 percentage of participants Interval 79.28 to 87.58	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Only those participants who achieved an objective response (CR or PR) were analyzed.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=202 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=234 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: DOR the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review	18.23 months Interval 12.94 to The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.	NA months Interval 19.02 to The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: FL Full Analysis Set. Only those participants who achieved an objective response (CR or PR) were analyzed. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=202 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=234 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 6 months	78.7 percent probability Interval 71.8 to 84.0	92.4 percent probability Interval 87.6 to 95.3	—	—
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 12 months	61.4 percent probability Interval 52.4 to 69.3	78.8 percent probability Interval 70.9 to 84.8	—	—
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 18 months	52.2 percent probability Interval 41.7 to 61.7	64.3 percent probability Interval 53.1 to 73.5	—	—
FL Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 2 years	35.5 percent probability Interval 21.3 to 50.0	58.2 percent probability Interval 44.9 to 69.4	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley with log-log transformation. Only participants who achieved an objective response (CR or PR) were analyzed.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=238 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review	18.83 months Interval 16.89 to The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.	NA months Interval 19.52 to The median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died.	—	—

SECONDARY outcome

Timeframe: up to 2 years

Population: Overall Full Analysis Set. Per the SAP, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population (main analysis population). Participants who achieved CR or PR were analyzed. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.

PET, CR: (1) score of 1 (no uptake above background), 2 (uptake ≤ mediastinum), or 3 (uptake > mediastinum but ≤ liver) with/without a residual mass for lymph nodes and extralymphatic sites (LN/ELS); (2) no evidence of FDG-avid disease in bone marrow; (3) no new lesions. PR: (1) score of 4 (uptake moderately > liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with Baseline and residual mass(es) of any size for LN/ELS; (2) residual uptake higher than in normal bone marrow but reduced from Baseline; (3) no new lesions. CT, CR: (1) target nodes/nodal masses regressed to ≤1.5 cm in LDi. no extra lymphatic site of disease; (2) absent nontarget lesions; (3) liver/spleen regressed to normal; (4) bone marrow normal by morphology; (5) no new lesions. PR: (1) ≥50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; (2) no increase in target lesions; (3) spleen regressed by >50% in length beyond normal; (4) no new lesions.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=238 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 6 months	81.5 percent probability Interval 75.5 to 86.2	93.1 percent probability Interval 88.9 to 95.7	—	—
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 12 months	65.6 percent probability Interval 57.6 to 72.5	80.0 percent probability Interval 73.0 to 85.3	—	—
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 18 months	56.5 percent probability Interval 46.9 to 65.0	65.7 percent probability Interval 55.8 to 73.8	—	—
Overall Population: Kaplan-Meier Estimates of DOR (the Time From the First Tumor Response [CR or PR as Per the Lugano 2014 Classification] Until the Time of the First Documented PD or Death From Any Cause, Whichever Was Earlier) by IRC Review 2 years	40.9 percent probability Interval 27.8 to 53.6	56.0 percent probability Interval 41.5 to 68.2	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. Only participants with available data were analyzed.

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) version 3 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Role Functioning	76.2 scores on a scale Standard Deviation 29.09	77.3 scores on a scale Standard Deviation 26.75	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Emotional Functioning	79.2 scores on a scale Standard Deviation 19.03	79.2 scores on a scale Standard Deviation 19.04	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Emotional Functioning	79.1 scores on a scale Standard Deviation 21.36	79.0 scores on a scale Standard Deviation 20.79	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Cognitive Functioning	87.0 scores on a scale Standard Deviation 17.25	88.0 scores on a scale Standard Deviation 19.06	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Cognitive Functioning	82.4 scores on a scale Standard Deviation 21.03	83.6 scores on a scale Standard Deviation 20.45	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Social Functioning	83.4 scores on a scale Standard Deviation 22.50	84.7 scores on a scale Standard Deviation 19.77	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Social Functioning	81.2 scores on a scale Standard Deviation 23.63	79.8 scores on a scale Standard Deviation 25.77	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Fatigue	26.9 scores on a scale Standard Deviation 24.71	27.0 scores on a scale Standard Deviation 23.43	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Fatigue	31.0 scores on a scale Standard Deviation 25.39	30.5 scores on a scale Standard Deviation 25.06	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Nausea and Vomiting	2.9 scores on a scale Standard Deviation 9.62	2.7 scores on a scale Standard Deviation 7.91	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Nausea and Vomiting	3.7 scores on a scale Standard Deviation 11.61	3.2 scores on a scale Standard Deviation 10.61	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Pain	17.6 scores on a scale Standard Deviation 23.97	16.0 scores on a scale Standard Deviation 21.06	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Pain	20.2 scores on a scale Standard Deviation 27.15	17.8 scores on a scale Standard Deviation 23.40	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Dyspnea	16.0 scores on a scale Standard Deviation 24.88	14.3 scores on a scale Standard Deviation 23.79	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Dyspnea	17.5 scores on a scale Standard Deviation 25.01	15.7 scores on a scale Standard Deviation 23.54	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Sleep	25.3 scores on a scale Standard Deviation 27.50	26.1 scores on a scale Standard Deviation 27.86	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Sleep	27.7 scores on a scale Standard Deviation 27.75	25.0 scores on a scale Standard Deviation 28.67	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Appetite Loss	11.4 scores on a scale Standard Deviation 20.45	10.2 scores on a scale Standard Deviation 23.21	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Appetite Loss	12.3 scores on a scale Standard Deviation 22.60	12.5 scores on a scale Standard Deviation 23.46	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Constipation	11.4 scores on a scale Standard Deviation 20.86	9.2 scores on a scale Standard Deviation 19.55	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Constipation	12.5 scores on a scale Standard Deviation 24.96	11.4 scores on a scale Standard Deviation 22.16	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Diarrhea	5.7 scores on a scale Standard Deviation 15.00	7.0 scores on a scale Standard Deviation 14.98	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Diarrhea	12.5 scores on a scale Standard Deviation 21.86	12.7 scores on a scale Standard Deviation 24.74	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Financial Difficulties	12.0 scores on a scale Standard Deviation 20.37	12.2 scores on a scale Standard Deviation 23.34	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Financial Difficulties	12.7 scores on a scale Standard Deviation 22.69	11.8 scores on a scale Standard Deviation 21.70	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Global Health Status	68.6 scores on a scale Standard Deviation 21.93	68.6 scores on a scale Standard Deviation 20.44	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Global Health Status	67.5 scores on a scale Standard Deviation 21.00	67.7 scores on a scale Standard Deviation 21.37	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Physical Functioning	84.1 scores on a scale Standard Deviation 19.54	84.7 scores on a scale Standard Deviation 17.44	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Physical Functioning	81.0 scores on a scale Standard Deviation 22.67	80.1 scores on a scale Standard Deviation 21.02	—	—
FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Role Functioning	82.8 scores on a scale Standard Deviation 24.72	83.1 scores on a scale Standard Deviation 22.72	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Only participants with available data were analyzed.

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) version 3 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Global Health Status	67.3 scores on a scale Standard Deviation 22.67	68.5 scores on a scale Standard Deviation 20.59	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Global Health Status	66.6 scores on a scale Standard Deviation 21.24	68.2 scores on a scale Standard Deviation 20.96	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Physical Functioning	82.8 scores on a scale Standard Deviation 20.20	83.2 scores on a scale Standard Deviation 18.07	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Physical Functioning	80.2 scores on a scale Standard Deviation 22.34	80.3 scores on a scale Standard Deviation 21.21	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Role Functioning	81.1 scores on a scale Standard Deviation 25.48	82.2 scores on a scale Standard Deviation 23.85	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Role Functioning	75.5 scores on a scale Standard Deviation 28.94	78.1 scores on a scale Standard Deviation 26.41	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Emotional Functioning	78.8 scores on a scale Standard Deviation 19.31	79.5 scores on a scale Standard Deviation 19.36	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Emotional Functioning	79.1 scores on a scale Standard Deviation 21.22	80.2 scores on a scale Standard Deviation 20.55	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Cognitive Functioning	86.8 scores on a scale Standard Deviation 17.03	87.6 scores on a scale Standard Deviation 18.79	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Cognitive Functioning	82.6 scores on a scale Standard Deviation 20.87	83.6 scores on a scale Standard Deviation 20.09	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Social functioning	82.3 scores on a scale Standard Deviation 23.47	84.6 scores on a scale Standard Deviation 19.94	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Social Functioning	81.5 scores on a scale Standard Deviation 22.86	81.0 scores on a scale Standard Deviation 25.37	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Fatigue	28.3 scores on a scale Standard Deviation 25.77	28.5 scores on a scale Standard Deviation 24.55	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Fatigue	31.0 scores on a scale Standard Deviation 25.08	30.1 scores on a scale Standard Deviation 24.52	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Nausea and Vomiting	2.9 scores on a scale Standard Deviation 9.16	2.8 scores on a scale Standard Deviation 9.31	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Nausea and Vomiting	4.1 scores on a scale Standard Deviation 12.34	3.4 scores on a scale Standard Deviation 10.56	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Pain	17.8 scores on a scale Standard Deviation 23.89	17.2 scores on a scale Standard Deviation 22.35	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Pain	19.7 scores on a scale Standard Deviation 26.42	17.9 scores on a scale Standard Deviation 23.73	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Dyspnea	17.2 scores on a scale Standard Deviation 26.27	15.8 scores on a scale Standard Deviation 24.79	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Dyspnea	18.5 scores on a scale Standard Deviation 25.80	16.2 scores on a scale Standard Deviation 24.50	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Sleep	25.9 scores on a scale Standard Deviation 27.20	27.8 scores on a scale Standard Deviation 29.41	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Sleep	26.8 scores on a scale Standard Deviation 27.81	25.7 scores on a scale Standard Deviation 29.33	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Appetite Loss	11.5 scores on a scale Standard Deviation 20.31	11.2 scores on a scale Standard Deviation 24.51	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Appetite Loss	12.9 scores on a scale Standard Deviation 23.40	12.6 scores on a scale Standard Deviation 23.35	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Constipation	10.8 scores on a scale Standard Deviation 20.46	9.8 scores on a scale Standard Deviation 20.70	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Constipation	12.7 scores on a scale Standard Deviation 24.62	11.7 scores on a scale Standard Deviation 23.37	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Diarrhea	5.6 scores on a scale Standard Deviation 14.81	7.5 scores on a scale Standard Deviation 16.02	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Diarrhea	13.7 scores on a scale Standard Deviation 23.53	12.5 scores on a scale Standard Deviation 23.95	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment Baseline, Financial Difficulties	12.5 scores on a scale Standard Deviation 21.20	11.9 scores on a scale Standard Deviation 22.58	—	—
Overall Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment End of Treatment, Financial Difficulties	12.2 scores on a scale Standard Deviation 21.99	11.4 scores on a scale Standard Deviation 21.12	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. Only participants with available data were analyzed.

The EQ-5D-5L contains a participant-reported score regarding health state measured on a visual analog scale (scores range from 0 [worst imaginable health state] to 100 [best imaginable health state]), and 5 questions on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 questions have 5 response levels: 1, no problems; 2, slight problems; 3, moderate problems; 4, severe problems; and 5, unable to/extreme problems.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=264 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=264 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Health State EQ-5D-5L Scores at Baseline and End of Treatment Baseline	73.6 scores on a scale Standard Deviation 19.13	72.5 scores on a scale Standard Deviation 18.15	—	—
FL Population: Health State EQ-5D-5L Scores at Baseline and End of Treatment End of Treatment	72.5 scores on a scale Standard Deviation 19.17	73.7 scores on a scale Standard Deviation 18.21	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Only participants with available data were analyzed.

The EQ-5D-5L contains a participant-reported score regarding health state measured on a visual analog scale (scores range from 0 [worst imaginable health state] to 100 [best imaginable health state]), and 5 questions on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 questions have 5 response levels: 1, no problems; 2, slight problems; 3, moderate problems; 4, severe problems; and 5, unable to/extreme problems.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=313 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=315 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Health State EQ-5D-5L Scores at Baseline and End of Treatment Baseline	72.6 scores on a scale Standard Deviation 19.67	72.2 scores on a scale Standard Deviation 18.78	—	—
Overall Population: Health State EQ-5D-5L Scores at Baseline and End of Treatment End of Treatment	72.0 scores on a scale Standard Deviation 19.21	74.2 scores on a scale Standard Deviation 18.37	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. Only participants with available data were analyzed.

The EQ-5D-5L contains a participant-reported score regarding health state measured on a visual analog scale (scores range from 0 [worst imaginable health state] to 100 [best imaginable health state]), and 5 questions on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 questions have 5 response levels: 1, no problems; 2, slight problems; 3, moderate problems; 4, severe problems; and 5, unable to/extreme problems.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 1	198 Participants	185 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 2	34 Participants	58 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 3	25 Participants	16 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 4	8 Participants	4 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 5	0 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 1	126 Participants	122 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 2	34 Participants	39 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 3	17 Participants	14 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 4	9 Participants	9 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 5	1 Participants	2 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 1	243 Participants	250 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 2	16 Participants	9 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 3	4 Participants	3 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 4	1 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 5	1 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 1	166 Participants	165 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 2	9 Participants	12 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 3	7 Participants	6 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 4	5 Participants	3 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 5	0 Participants	0 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 1	184 Participants	179 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 2	50 Participants	59 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 3	26 Participants	17 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 4	4 Participants	4 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 5	1 Participants	5 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 1	114 Participants	107 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 2	47 Participants	58 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 3	16 Participants	13 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 4	5 Participants	7 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 5	5 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 1	141 Participants	144 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 2	82 Participants	92 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 3	34 Participants	25 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 4	7 Participants	2 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 5	1 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 1	104 Participants	106 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 2	51 Participants	55 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 3	21 Participants	17 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 4	8 Participants	8 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 5	3 Participants	0 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 1	152 Participants	138 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 2	79 Participants	98 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 3	26 Participants	22 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 4	7 Participants	5 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 5	1 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 1	103 Participants	107 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 2	60 Participants	58 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 3	20 Participants	18 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 4	4 Participants	1 Participants	—	—
FL Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 5	0 Participants	2 Participants	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Only participants with available data were analyzed.

The EQ-5D-5L contains a participant-reported score regarding health state measured on a visual analog scale (scores range from 0 [worst imaginable health state] to 100 [best imaginable health state]), and 5 questions on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 questions have 5 response levels: 1, no problems; 2, slight problems; 3, moderate problems; 4, severe problems; and 5, unable to/extreme problems.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 1	226 Participants	212 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 2	47 Participants	68 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 3	30 Participants	24 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 4	11 Participants	10 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Mobility, Score 5	0 Participants	1 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 1	149 Participants	149 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 2	47 Participants	46 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 3	22 Participants	17 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 4	10 Participants	13 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Mobility, Score 5	1 Participants	3 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 1	284 Participants	294 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 2	22 Participants	12 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 3	6 Participants	4 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 4	1 Participants	2 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Self-care, Score 5	1 Participants	3 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 1	202 Participants	198 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 2	15 Participants	15 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 3	7 Participants	9 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 4	5 Participants	5 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Self-care, Score 5	0 Participants	1 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 1	208 Participants	207 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 2	64 Participants	74 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 3	33 Participants	23 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 4	5 Participants	6 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Usual Activities, Score 5	4 Participants	5 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 1	135 Participants	133 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 2	62 Participants	68 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 3	21 Participants	15 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 4	6 Participants	11 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Usual Activities, Score 5	5 Participants	1 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 1	161 Participants	168 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 2	104 Participants	108 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 3	40 Participants	35 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 4	8 Participants	3 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Pain/Discomfort, Score 5	1 Participants	1 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 1	124 Participants	129 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 2	70 Participants	68 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 3	23 Participants	21 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 4	9 Participants	10 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Pain/Discomfort, Score 5	3 Participants	0 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 1	177 Participants	173 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 2	98 Participants	110 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 3	30 Participants	25 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 4	8 Participants	6 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment Baseline, Anxiety/Depression, Score 5	1 Participants	1 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 1	126 Participants	136 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 2	74 Participants	68 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 3	24 Participants	20 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 4	5 Participants	2 Participants	—	—
Overall Population: Number of Participants With the Indicated Scores for the Five EQ-5D-5L Domains/Questions at Baseline and End of Treatment End of Treatment, Anxiety/Depression, Score 5	0 Participants	2 Participants	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: FL Full Analysis Set. Only participants with available data were analyzed.

The FACT-Lymphoma (v4) is composed of 42 items with a 5-point Likert-type scale and 5 subscales. Physical well-being (PWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Social/family well-being (SWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Emotional well-being (EWB) subscale: 6 items measured on 0- to 4-point scale; total score = 0-24. Functional well-being (FWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Lymphoma (LymS) subscale includes 15 items; total score = 0-60. Three total scores can be derived by adding the subscales: FACT-Lymphoma Trial Outcome Index (TOI): (PWB score) + (FWB score) + (LymS score); total score = 0-116. FACT-G total score: (PWB score) + (SWB score) + (EWB score) + (FWB score); total score = 0-108. FACT-Lymphoma total score: (PWB score) + (SWB score) + (EWB score) + (FWB score) + (LymS score); total score = 0-168. The higher the score, the better the quality of life.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=275 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=273 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, PWB subscale	24.3 scores on a scale Standard Deviation 4.07	24.0 scores on a scale Standard Deviation 4.26	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, PWB subscale	23.2 scores on a scale Standard Deviation 5.42	23.5 scores on a scale Standard Deviation 4.68	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, SWB subscale	20.5 scores on a scale Standard Deviation 5.92	20.9 scores on a scale Standard Deviation 5.82	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, SWB subscale	19.9 scores on a scale Standard Deviation 5.31	19.9 scores on a scale Standard Deviation 5.95	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, EWB subscale	18.3 scores on a scale Standard Deviation 4.06	18.2 scores on a scale Standard Deviation 4.21	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, EWB subscale	18.1 scores on a scale Standard Deviation 4.80	18.3 scores on a scale Standard Deviation 4.39	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, FWB subscale	17.8 scores on a scale Standard Deviation 5.98	17.6 scores on a scale Standard Deviation 6.12	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, FWB subscale	16.3 scores on a scale Standard Deviation 6.19	16.5 scores on a scale Standard Deviation 6.24	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, FACT-LymS	47.7 scores on a scale Standard Deviation 7.88	47.7 scores on a scale Standard Deviation 8.87	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, FACT-LymS	48.0 scores on a scale Standard Deviation 8.98	48.0 scores on a scale Standard Deviation 9.41	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, FACT-Lymphoma TOI	89.8 scores on a scale Standard Deviation 15.51	89.3 scores on a scale Standard Deviation 16.07	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, FACT-Lymphoma TOI	87.3 scores on a scale Standard Deviation 18.59	88.0 scores on a scale Standard Deviation 17.80	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, FACT-G Total Score	80.9 scores on a scale Standard Deviation 15.08	80.7 scores on a scale Standard Deviation 15.04	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, FACT-G Total Score	77.3 scores on a scale Standard Deviation 17.02	78.3 scores on a scale Standard Deviation 16.63	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment Baseline, FACT-Lymphoma Total Score	128.6 scores on a scale Standard Deviation 21.27	128.4 scores on a scale Standard Deviation 21.81	—	—
FL Population: Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) Scores at Baseline and End of Treatment End of Treatment, FACT-Lymphoma Total Score	125.2 scores on a scale Standard Deviation 24.65	126.1 scores on a scale Standard Deviation 24.39	—	—

SECONDARY outcome

Timeframe: up to approximately 34 months

Population: Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Only participants with available data were analyzed.

The FACT-Lymphoma (v4) is composed of 42 items with a 5-point Likert-type scale and 5 subscales. Physical well-being (PWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Social/family well-being (SWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Emotional well-being (EWB) subscale: 6 items measured on 0- to 4-point scale; total score = 0-24. Functional well-being (FWB) subscale: 7 items measured on 0- to 4-point scale; total score = 0-28. Lymphoma (LymS) subscale includes 15 items; total score = 0-60. Three total scores can be derived by adding the subscales: FACT-Lymphoma Trial Outcome Index (TOI): (PWB score) + (FWB score) + (LymS score); total score = 0-116. FACT-G total score: (PWB score) + (SWB score) + (EWB score) + (FWB score); total score = 0-108. FACT-Lymphoma total score: (PWB score) + (SWB score) + (EWB score) + (FWB score) + (LymS score); total score = 0-168. The higher the score, the better the quality of life.

Outcome measures

Measure	FL and MZL: Placebo + Rituximab + Lenalidomide n=328 Participants Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	FL: Tafasitamab + Rituximab + Lenalidomide n=326 Participants Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Tafasitamab + Rituximab + Lenalidomide Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	MZL: Placebo + Rituximab + Lenalidomide Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, PWB subscale	24.1 scores on a scale Standard Deviation 4.20	23.8 scores on a scale Standard Deviation 4.41	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, PWB subscale	23.2 scores on a scale Standard Deviation 5.21	23.6 scores on a scale Standard Deviation 4.71	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, SWB subscale	20.2 scores on a scale Standard Deviation 6.06	20.8 scores on a scale Standard Deviation 5.82	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, SWB subscale	19.8 scores on a scale Standard Deviation 5.34	20.2 scores on a scale Standard Deviation 5.89	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, EWB subscale	18.1 scores on a scale Standard Deviation 4.12	18.2 scores on a scale Standard Deviation 4.20	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, EWB subscale	18.1 scores on a scale Standard Deviation 4.67	18.7 scores on a scale Standard Deviation 4.31	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, FWB subscale	17.3 scores on a scale Standard Deviation 6.08	17.3 scores on a scale Standard Deviation 6.19	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, FWB subscale	16.2 scores on a scale Standard Deviation 6.22	16.8 scores on a scale Standard Deviation 6.29	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, FACT-LymS	47.6 scores on a scale Standard Deviation 7.98	47.4 scores on a scale Standard Deviation 8.91	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, FACT-LymS	48.2 scores on a scale Standard Deviation 8.71	48.7 scores on a scale Standard Deviation 9.17	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, FACT-Lymphoma TOI	89.0 scores on a scale Standard Deviation 15.72	88.7 scores on a scale Standard Deviation 16.40	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, FACT-Lymphoma TOI	87.4 scores on a scale Standard Deviation 18.14	89.0 scores on a scale Standard Deviation 17.74	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, FACT-G Total Score	79.7 scores on a scale Standard Deviation 15.43	80.2 scores on a scale Standard Deviation 15.39	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, FACT-G Total Score	77.1 scores on a scale Standard Deviation 16.80	79.2 scores on a scale Standard Deviation 16.65	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment Baseline, FACT-Lymphoma Total Score	127.3 scores on a scale Standard Deviation 21.57	127.7 scores on a scale Standard Deviation 22.18	—	—
Overall Population: FACT-Lym Scores at Baseline and End of Treatment End of Treatment, FACT-Lymphoma Total Score	125.2 scores on a scale Standard Deviation 24.18	127.8 scores on a scale Standard Deviation 24.26	—	—

Adverse Events

Tafasitamab + Rituximab + Lenalidomide

Serious events: 125 serious events

Other events: 318 other events

Deaths: 22 deaths

Placebo + Rituximab + Lenalidomide

Serious events: 110 serious events

Other events: 315 other events

Deaths: 24 deaths

Total

Serious events: 235 serious events

Other events: 633 other events

Deaths: 46 deaths

Serious adverse events

Measure	Tafasitamab + Rituximab + Lenalidomide n=327 participants at risk Participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	Placebo + Rituximab + Lenalidomide n=325 participants at risk Participants with FL or MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	Total n=652 participants at risk Total
Gastrointestinal disorders Abdominal pain	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	1.5% 5/325 • Number of events 5 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.77% 5/652 • Number of events 5 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Abdominal pain lower	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Acute coronary syndrome	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Renal and urinary disorders Acute kidney injury	2.8% 9/327 • Number of events 9 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	1.8% 6/325 • Number of events 6 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	2.3% 15/652 • Number of events 15 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Acute myocardial infarction	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Acute pulmonary oedema	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma gastric	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Anaemia	0.92% 3/327 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.77% 5/652 • Number of events 5 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Anal infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Anal ulcer	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Angina unstable	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Psychiatric disorders Anxiety	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Appendicitis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Arthritis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Asthenia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Atelectasis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Atrial fibrillation	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Atypical pneumonia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Back pain	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Bacteraemia	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Bacterial sepsis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Hepatobiliary disorders Bile duct stone	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Breast abscess	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Bronchitis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Bronchopulmonary aspergillosis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Investigations C-reactive protein increased	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations COVID-19	6.4% 21/327 • Number of events 27 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	2.5% 8/325 • Number of events 9 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.4% 29/652 • Number of events 36 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations COVID-19 pneumonia	5.2% 17/327 • Number of events 19 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	2.2% 7/325 • Number of events 8 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	3.7% 24/652 • Number of events 27 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Renal and urinary disorders Calculus urinary	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Campylobacter gastroenteritis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Candida infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Carcinoid tumour in the large intestine	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Cardiac arrest	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Cardiac failure	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Cellulitis	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.61% 4/652 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Cerebral haemorrhage	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Cervicobrachial syndrome	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Hepatobiliary disorders Cholecystitis acute	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Clostridium difficile infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Cognitive disorder	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Colitis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Psychiatric disorders Confusional state	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Immune system disorders Cytokine release syndrome	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Death	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Decreased appetite	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Deep vein thrombosis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Device related infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Device related thrombosis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Diarrhoea	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.92% 3/325 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.61% 4/652 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Embolism	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Embolism venous	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Empyema	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Enteritis infectious	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Enterobacter bacteraemia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Enterocolitis haemorrhagic	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Epilepsy	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Erysipelas	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Escherichia sepsis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Fall	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Fatigue	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Febrile infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Febrile neutropenia	2.8% 9/327 • Number of events 10 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	3.1% 10/325 • Number of events 11 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	2.9% 19/652 • Number of events 21 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Femoral neck fracture	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Food poisoning	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Gastroenteritis	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Gastroenteritis rotavirus	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Generalised oedema	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Immune system disorders Haemophagocytic lymphohistiocytosis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Haemophilus bacteraemia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Headache	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Hepatobiliary disorders Hepatobiliary disease	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Hepatobiliary disorders Hepatosplenomegaly	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Hip fracture	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Hyperglycaemia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Immune system disorders Hypersensitivity	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Hypertensive crisis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Hyperthermia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Immune system disorders Hypogammaglobulinaemia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Hyponatraemia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Hypotension	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Ileus	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Infection	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Infective exacerbation of asthma	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Influenza	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Infusion related reaction	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Laryngitis	0.31% 1/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Investigations Liver function test increased	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Lower respiratory tract infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.31% 1/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Lymphatic fistula	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Lymphoedema	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Malaise	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Moraxella infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Multiple organ dysfunction syndrome	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Myocardial infarction	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Myopericarditis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Neutropenia	0.61% 2/327 • Number of events 5 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.92% 3/325 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.77% 5/652 • Number of events 9 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Non-cardiac chest pain	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Norovirus infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Organising pneumonia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Pancreatitis acute	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Parainfluenzae virus infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Pelvic fracture	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Peripheral artery occlusion	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Peripheral ischaemia	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Peritonitis bacterial	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.61% 4/652 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pneumocystis jirovecii pneumonia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pneumonia	7.6% 25/327 • Number of events 33 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.6% 15/325 • Number of events 18 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.1% 40/652 • Number of events 51 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pneumonia adenoviral	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pneumonia moraxella	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pneumonia pneumococcal	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pneumonia viral	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Presyncope	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Progressive multifocal leukoencephalopathy	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Prostatic abscess	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pseudomonal sepsis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pseudomonal skin infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pulmonary sepsis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.62% 2/325 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.46% 3/652 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Pyelonephritis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Pyrexia	1.8% 6/327 • Number of events 7 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	3.4% 11/325 • Number of events 12 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	2.6% 17/652 • Number of events 19 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Skin and subcutaneous tissue disorders Rash	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Skin and subcutaneous tissue disorders Rash maculo-papular	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Skin and subcutaneous tissue disorders Rash vesicular	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Renal and urinary disorders Renal failure	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Respiratory tract infection	0.92% 3/327 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.92% 3/325 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.92% 6/652 • Number of events 6 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Rib fracture	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Sepsis	1.2% 4/327 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	1.5% 5/325 • Number of events 5 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	1.4% 9/652 • Number of events 9 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Septic shock	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Seroma	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Immune system disorders Serum sickness	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Cardiac disorders Sinus node dysfunction	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Skin infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Small intestinal obstruction	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Splenic rupture	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Staphylococcal bacteraemia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Staphylococcal infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Syncope	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Thrombocytopenia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour flare	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.92% 3/325 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.61% 4/652 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Tumour lysis syndrome	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Upper respiratory tract infection	0.61% 2/327 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Urinary tract infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.92% 3/325 • Number of events 3 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.61% 4/652 • Number of events 4 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Urosepsis	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Varicella zoster pneumonia	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Varicella zoster virus infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Vena cava thrombosis	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.00% 0/325 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Viral upper respiratory tract infection	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Vomiting	0.00% 0/327 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.15% 1/652 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Wound infection	0.31% 1/327 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 1/325 • Number of events 1 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	0.31% 2/652 • Number of events 2 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).

Other adverse events

Measure	Tafasitamab + Rituximab + Lenalidomide n=327 participants at risk Participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	Placebo + Rituximab + Lenalidomide n=325 participants at risk Participants with FL or MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.	Total n=652 participants at risk Total
Gastrointestinal disorders Abdominal pain	7.6% 25/327 • Number of events 33 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	8.6% 28/325 • Number of events 30 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	8.1% 53/652 • Number of events 63 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Investigations Alanine aminotransferase increased	5.8% 19/327 • Number of events 28 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.1% 23/325 • Number of events 36 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.4% 42/652 • Number of events 64 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Anaemia	16.2% 53/327 • Number of events 97 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	14.2% 46/325 • Number of events 73 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	15.2% 99/652 • Number of events 170 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Arthralgia	7.3% 24/327 • Number of events 25 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	8.3% 27/325 • Number of events 36 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.8% 51/652 • Number of events 61 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Asthenia	13.5% 44/327 • Number of events 58 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	10.8% 35/325 • Number of events 48 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	12.1% 79/652 • Number of events 106 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Back pain	9.8% 32/327 • Number of events 41 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	5.5% 18/325 • Number of events 21 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.7% 50/652 • Number of events 62 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Bronchitis	5.2% 17/327 • Number of events 21 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.3% 14/325 • Number of events 14 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.8% 31/652 • Number of events 35 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations COVID-19	26.3% 86/327 • Number of events 98 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	22.2% 72/325 • Number of events 81 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	24.2% 158/652 • Number of events 179 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Chills	4.3% 14/327 • Number of events 14 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	5.2% 17/325 • Number of events 18 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.8% 31/652 • Number of events 32 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Constipation	27.5% 90/327 • Number of events 110 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	24.9% 81/325 • Number of events 100 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	26.2% 171/652 • Number of events 210 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Cough	19.0% 62/327 • Number of events 81 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	16.9% 55/325 • Number of events 69 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	17.9% 117/652 • Number of events 150 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Decreased appetite	11.0% 36/327 • Number of events 39 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	9.2% 30/325 • Number of events 32 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	10.1% 66/652 • Number of events 71 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Diarrhoea	37.6% 123/327 • Number of events 219 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	31.1% 101/325 • Number of events 162 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	34.4% 224/652 • Number of events 381 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Dizziness	8.0% 26/327 • Number of events 34 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.1% 23/325 • Number of events 28 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.5% 49/652 • Number of events 62 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Dyspnoea	6.7% 22/327 • Number of events 26 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	9.2% 30/325 • Number of events 32 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	8.0% 52/652 • Number of events 58 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Fatigue	20.5% 67/327 • Number of events 80 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	16.3% 53/325 • Number of events 64 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	18.4% 120/652 • Number of events 144 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Nervous system disorders Headache	10.4% 34/327 • Number of events 47 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.7% 25/325 • Number of events 30 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	9.0% 59/652 • Number of events 77 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Metabolism and nutrition disorders Hypokalaemia	8.3% 27/327 • Number of events 44 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	12.6% 41/325 • Number of events 60 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	10.4% 68/652 • Number of events 104 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Vascular disorders Hypotension	6.1% 20/327 • Number of events 22 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.3% 14/325 • Number of events 16 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	5.2% 34/652 • Number of events 38 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Injury, poisoning and procedural complications Infusion related reaction	15.9% 52/327 • Number of events 58 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	15.1% 49/325 • Number of events 61 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	15.5% 101/652 • Number of events 119 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Psychiatric disorders Insomnia	7.6% 25/327 • Number of events 25 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.1% 23/325 • Number of events 23 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.4% 48/652 • Number of events 48 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Muscle spasms	16.2% 53/327 • Number of events 68 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	17.5% 57/325 • Number of events 64 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	16.9% 110/652 • Number of events 132 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Myalgia	6.1% 20/327 • Number of events 21 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.6% 15/325 • Number of events 20 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	5.4% 35/652 • Number of events 41 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Nasopharyngitis	5.8% 19/327 • Number of events 22 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.5% 21/325 • Number of events 22 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.1% 40/652 • Number of events 44 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Nausea	18.0% 59/327 • Number of events 76 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	14.5% 47/325 • Number of events 58 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	16.3% 106/652 • Number of events 134 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Neutropenia	50.2% 164/327 • Number of events 470 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	47.4% 154/325 • Number of events 388 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	48.8% 318/652 • Number of events 858 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Investigations Neutrophil count decreased	7.3% 24/327 • Number of events 65 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.1% 23/325 • Number of events 60 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.2% 47/652 • Number of events 125 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Oedema peripheral	7.6% 25/327 • Number of events 27 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	13.5% 44/325 • Number of events 45 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	10.6% 69/652 • Number of events 72 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	8.9% 29/327 • Number of events 37 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.3% 14/325 • Number of events 15 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.6% 43/652 • Number of events 52 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Musculoskeletal and connective tissue disorders Pain in extremity	7.0% 23/327 • Number of events 28 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	3.4% 11/325 • Number of events 12 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	5.2% 34/652 • Number of events 40 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Skin and subcutaneous tissue disorders Pruritus	15.6% 51/327 • Number of events 70 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	11.7% 38/325 • Number of events 49 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	13.7% 89/652 • Number of events 119 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
General disorders Pyrexia	18.3% 60/327 • Number of events 85 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	15.1% 49/325 • Number of events 63 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	16.7% 109/652 • Number of events 148 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Skin and subcutaneous tissue disorders Rash	22.0% 72/327 • Number of events 103 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	21.5% 70/325 • Number of events 115 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	21.8% 142/652 • Number of events 218 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Skin and subcutaneous tissue disorders Rash maculo-papular	5.5% 18/327 • Number of events 22 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.9% 16/325 • Number of events 26 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	5.2% 34/652 • Number of events 48 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Respiratory tract infection	6.4% 21/327 • Number of events 33 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	8.0% 26/325 • Number of events 32 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.2% 47/652 • Number of events 65 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Blood and lymphatic system disorders Thrombocytopenia	14.7% 48/327 • Number of events 121 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	18.2% 59/325 • Number of events 91 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	16.4% 107/652 • Number of events 212 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Upper respiratory tract infection	8.6% 28/327 • Number of events 37 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	11.1% 36/325 • Number of events 40 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	9.8% 64/652 • Number of events 77 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Infections and infestations Urinary tract infection	8.0% 26/327 • Number of events 34 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.5% 21/325 • Number of events 27 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	7.2% 47/652 • Number of events 61 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).
Gastrointestinal disorders Vomiting	7.3% 24/327 • Number of events 28 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	4.9% 16/325 • Number of events 20 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).	6.1% 40/652 • Number of events 48 • from signing of the Informed Consent Form to up to 90 days post-treatment (up to approximately 3 years) As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Safety was not expected to be different between each histological subtype (FL versus MZL).

Additional Information

Study Director

Incyte Corporation

Phone: 1-855-463-3463

Email: medinfo@incyte.com

Results disclosure agreements

• Principal investigator is a sponsor employee Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.
• Publication restrictions are in place

Restriction type: OTHER